![](https://www.texasretina.com/wp-content/uploads/2022/06/Abbey-Ashkan-08-Blog-Head-Shot-1.jpg)
Dr. Abbey Presented Key Results of DAVIO 2 Clinical Trial for Wet AMD at Retina World Congress
At the recently held 2024 Retina World Congress Meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented topline results from the DAVIO 2 clinical trial investigating EYP-1901 (Duravyu),
read more![](https://www.texasretina.com/wp-content/uploads/2023/10/Abbey-cropped.jpg)
Three New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of retinal conditions, and our physicians remain committed to participating in clinical trials that will improve care for our patients.
read more![](https://www.texasretina.com/wp-content/uploads/2019/03/eye-1986661_1920-1534x792.jpg)
New Treatment for Wet AMD and Diabetic Eye Disease Reduces Treatment Burden for Patients by Extending Dosing Intervals
On August 18, 2023, the U.S. Food and Drug Administration (FDA) approved Eylea HD (aflibercept), a high-dose version of Eylea, for the treatment of several retinal conditions, including advanced neovascular age-related macular
read more![](https://www.texasretina.com/wp-content/uploads/2019/03/eye-1986661_1920-1534x792.jpg)
New Clinical Trials Available at Texas Retina
Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one
read more